PMS-INDAPAMIDE 2.5 MG
INDAPAMIDE : 2.5 MG · DIN 02239620 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-INDAPAMIDE?
PMS-INDAPAMIDE 2.5 MG contains INDAPAMIDE : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02239620, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-May-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-INDAPAMIDE used for?
Management of essential hypertension. May be used alone for mild to moderate cases or as part of multiple drug regimens.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02239620 |
|---|---|
| Brand name | PMS-INDAPAMIDE |
| Generic / active ingredient | INDAPAMIDE : 2.5 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03BA11 INDAPAMIDE |
| AHFS class | 40:28.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-May-2018 |
| Original market date | 1999-02-18 00:00:00 |
How is it administered?
Initial: 1.25 mg once daily in the morning. May increase to 2.5 mg daily after 4-8 weeks if response is insufficient. Maximum dose: 2.5 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C-30°C.
How is it supplied?
1.25 mg: HDPE bottles of 30 and 100, blister packs of 30. 2.5 mg: Pink round tablets (packaging details cut off in text).
Contraindications
Hypersensitivity to indapamide/sulfonamides; severe renal failure (CrCl < 30 mL/min); hepatic encephalopathy; hypokalemia; pregnancy; lactation; combinations with certain anti-arrhythmic agents.
Warnings and precautions
Do not exceed 2.5 mg/day. Risk of severe hypokalemia and cardiac arrhythmias. Monitor electrolytes, uric acid, and glucose. Discontinue if hepatic encephalopathy or photosensitivity occurs.
What can be used instead?
Other Canadian products sharing ATC code C03BA11 INDAPAMIDE. 4 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-INDAPAMIDE 1.25 MG TABLETS | 1.25 MG | TABLET | APOTEX INC | MARKETED | DIN 02245246 |
| APO-INDAPAMIDE 2.5MG TABLETS | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02223678 |
| MYLAN-INDAPAMIDE | 1.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02240067 |
| MYLAN-INDAPAMIDE | 2.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02153483 |
| DOM-INDAPAMIDE TABLETS 1.25MG | 1.25 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239913 |
| DOM-INDAPAMIDE TABLETS 2.5MG | 2.5 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239917 |
| INDAPAMIDE | 1.25 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02445824 |
| INDAPAMIDE | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02445832 |
| INDAPAMIDE | 2.5 MG | TABLET | SANIS HEALTH INC | CANCELLED PRE MARKET | DIN 02365324 |
| INDAPAMIDE HEMIHYDRATE 1.25MG - TAB | 1.25 MG | TABLET | PROVAL PHARMA DIVISION OF SERVIER CANADA INC | CANCELLED POST MARKET | DIN 02227339 |
Who else supplies INDAPAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INDAPAMIDE appears in 129 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.